Literature DB >> 8806794

Effect of irradiation on cytokine production, MHC antigen expression, and vaccine potential of interleukin-2 and interferon-gamma gene-modified melanoma cells.

Z Abdel-Wahab1, M M Dar, D Hester, C Vervaert, R Gangavalli, J Barber, T L Darrow, H F Seigler.   

Abstract

Recent studies have shown that tumor cells transduced with interleukin-2 (IL-2) or interferon-gamma (IFN-gamma) genes stimulated a potent and specific antitumor immunity in experimental animals. For use as a human vaccine, tumor cells must be inactivated by irradiation to ensure the arrest of their growth. This study was undertaken to examine the effects of irradiation (10,000 rad) on the growth characteristics and vaccine potential of IL-2 and IFN-gamma-modified human melanomas and B16 murine melanoma. Irradiation caused cessation of cell growth and gradual reduction of cell number. Irradiated melanoma cells displayed 1.5 to 10-fold increases in the surface expression of MHC class I and/or class II antigens. The increases in MHC antigens persisted for 7-14 days postirradiation and then declined thereafter. Furthermore, IL-2- and IFN-gamma-transduced melanoma cells showed enhanced expression of the cytokine mRNA and increased cytokine secretion after irradiation. The effect of irradiation on the vaccine potential of the transduced cells was examined in C57BL/ 6 mice by prophylactic immunization and immunotherapy, and in nude mice by mixed transplantation assays. The irradiated, cytokine-transduced B16 cell vaccine was as or more effective than the unirradiated vaccine. These irradiated vaccines protected the animals against a challenging tumorigenic dose of B16 parental cells and suppressed the growth of 4-day-established B16 lung metastases. The ability of the irradiated IL-2-transduced human melanomas to inhibit the growth of admixed parental melanoma cells was retained but was less efficacious than unirradiated cells. The results suggest that irradiation does not abrogate the vaccine potential of IL-2- and IFN-gamma-transduced melanomas. These findings have implications for designing specific active immunotherapy protocols utilizing cytokine gene-modified tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8806794     DOI: 10.1006/cimm.1996.0200

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  10 in total

Review 1.  Cancer treatment and the KIR-HLA system: an overview.

Authors:  Patrizia Leone; Valli De Re; Angelo Vacca; Franco Dammacco; Vito Racanelli
Journal:  Clin Exp Med       Date:  2017-02-10       Impact factor: 3.984

2.  Enhancement of B7-1 (CD80) expression on B-lymphoma cells by irradiation.

Authors:  A Seo; F Ishikawa; H Nakano; H Nakazaki; K Kobayashi; T Kakiuchi
Journal:  Immunology       Date:  1999-04       Impact factor: 7.397

3.  HLA-E and HLA-F Are Overexpressed in Glioblastoma and HLA-E Increased After Exposure to Ionizing Radiation.

Authors:  Tomas Hrbac; Alena Kopkova; Frantisek Siegl; Marek Vecera; Michaela Ruckova; Tomas Kazda; Radim Jancalek; Michal Hendrych; Marketa Hermanova; Vaclav Vybihal; Pavel Fadrus; Martin Smrcka; Filip Sokol; Vaclav Kubes; Radim Lipina; Ondrej Slaby; Leos Kren; Jiri Sana
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

4.  A randomized controlled trial to investigate the influence of low dose radiotherapy on immune stimulatory effects in liver metastases of colorectal cancer.

Authors:  Christoph Reissfelder; Carmen Timke; Hubertus Schmitz-Winnenthal; Nuh N Rahbari; Moritz Koch; Felix Klug; Falk Roeder; Lutz Edler; Jürgen Debus; Markus W Büchler; Philipp Beckhove; Peter E Huber; Jürgen Weitz
Journal:  BMC Cancer       Date:  2011-09-30       Impact factor: 4.430

5.  Radiation, inflammation, and immune responses in cancer.

Authors:  Gabriele Multhoff; Jürgen Radons
Journal:  Front Oncol       Date:  2012-06-04       Impact factor: 6.244

6.  HLA class I expression and its alteration by preoperative hyperthermo-chemoradiotherapy in patients with rectal cancer.

Authors:  Hiro Sato; Yoshiyuki Suzuki; Munenori Ide; Toshihide Katoh; Shin-Ei Noda; Ken Ando; Takahiro Oike; Yuya Yoshimoto; Noriyuki Okonogi; Kousaku Mimura; Takayuki Asao; Hiroyuki Kuwano; Takashi Nakano
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

7.  A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial).

Authors:  Seyer Safi; Philipp Beckhove; Arne Warth; Axel Benner; Falk Roeder; Stefan Rieken; Juergen Debus; Hendrik Dienemann; Hans Hoffmann; Peter E Huber
Journal:  BMC Cancer       Date:  2015-12-19       Impact factor: 4.430

Review 8.  The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.

Authors:  Akhil Shukla; Maryse Cloutier; Madanraj Appiya Santharam; Sheela Ramanathan; Subburaj Ilangumaran
Journal:  Int J Mol Sci       Date:  2021-02-17       Impact factor: 5.923

9.  Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.

Authors:  Lewis Zhichang Shi; James A Bonner
Journal:  Int J Mol Sci       Date:  2021-11-14       Impact factor: 5.923

10.  Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports.

Authors:  Sarah A Milgrom; Yago Nieto; Chelsea C Pinnix; Grace L Smith; Christine F Wogan; Gabriela Rondon; L Jeffrey Medeiros; Partow Kebriaei; Bouthaina S Dabaja
Journal:  J Med Case Rep       Date:  2016-07-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.